RecruitingNon-small Cell Lung Cancer

A Clinical Study of Calderasib (MK-1084) and Other Treatments for Participants With Non-Small Cell Lung Cancer (MK-1084-007/KANDLELIT-007)

Eligible age

18+ yrs

Accepts

All genders

Locations

9 states

Healthy volunteers

See if you qualify for this study

Answer a few quick questions about your location and health. Takes about a minute.

Check my eligibility →

About this study

Researchers want to learn if the study medicines calderasib and subcutaneous (SC) pembrolizumab can be used to treat non-small cell lung cancer (NSCLC) when given together. Calderasib is a targeted therapy for the KRAS G12C mutation. The goal of this study is to learn if people who receive calderasib with SC pembrolizumab live longer without the cancer growing or spreading than in people who receive SC pembrolizumab with chemotherapy.

Sponsor: Merck Sharp & Dohme LLC

You may qualify if…

✓ The main inclusion criteria include but are not limited to the following:
✓ Has nonsquamous NSCLC (Stage IIIB, Stage IIIC) not eligible for curative resection or chemoradiation or Stage IV: M1a, M1b, or M1c
✓ If human immunodeficiency virus (HIV) positive, must have well controlled HIV on antiretroviral therapy (ART)

You may not qualify if…

✕ The main exclusion criteria include but are not limited to the following:
✕ Has diagnosis of small cell lung cancer or, for mixed tumors, presence of small cell elements
✕ Has active inflammatory bowel disease requiring immunosuppressive medication or previous clear history of inflammatory bowel disease (e.g., Crohn's disease, ulcerative colitis, or chronic diarrhea)
✕ Has uncontrolled, significant cardiovascular disease or cerebrovascular disease
✕ Has a gastrointestinal disorder affecting absorption
✕ Is HIV positive and has a history of Kaposi's sarcoma and/or Multicentric Castleman's Disease
✕ Has received prior systemic anticancer therapy for their advanced or metastatic NSCLC
✕ Has known additional malignancy that is progressing or has required active treatment within the past 3 years